Johnson and Johnson Exceeds Market Forecasts Despite Impacts from Trump Drug Pricing Deal
Johnson and Johnson issued a strong 2026 outlook and reported quarterly earnings that beat expectations. The results came despite costs from a drug pricing deal.
洞察:
Johnson & Johnson on Wednesday issued a 2026 financial forecast that surpassed Wall Street expectations, even as the company manages significant costs related to a drug pricing agreement with the administration of Donald Trump donald trump. The healthcare giant projected full-year 2026 sales between $99.5 billion and $100.5 billion, higher than the analyst consensus of $98.9 billion. Additionally, the company expects a profit range of $11.43 to $11.63 per share, which also edges out the $11.45 per share estimated by market analysts.
These projections come as Johnson & Johnsonnavigates material headwinds stemming from federal policy in the US 
US. The company disclosed that its negotiated drug pricing deal with the Trump administration will cost it hundreds of millions of dollars. Furthermore, the firm anticipates approximately $500 million in tariff impacts specifically affecting its medical devices business. Johnson & Johnsonis notably one of 16 major pharmaceutical companies to reach such agreements, which lower drug prices in exchange for exemptions from certain tariffs imposed by the administration of Donald Trump.
US. The company disclosed that its negotiated drug pricing deal with the Trump administration will cost it hundreds of millions of dollars. Furthermore, the firm anticipates approximately $500 million in tariff impacts specifically affecting its medical devices business. Johnson & Johnsonis notably one of 16 major pharmaceutical companies to reach such agreements, which lower drug prices in exchange for exemptions from certain tariffs imposed by the administration of Donald Trump.
